CD274 and neoplasm: Immune checkpoint inhibitors, including PD-1/PD-L1 and CTLA-4 antagonists, effectively reverse the immune evasion mechanisms employed by tumor cells, thereby enhancing the body’s immune response against malignancies, thereby enhancing the antitumor activity of T cells.